IP Library Patent Application 17162065
Patent Application
App. No. 17/162,065

DOSAGE RECOMMENDATION FACILITATED BY ARTIFICIAL INTELLIGENCE

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
17/162,065
Abstract

Disclosed herein are techniques related to glucose level management without carbohydrate counting. The techniques may involve obtaining contextual information for a meal, predicting amounts of glucose to be absorbed into a bloodstream of the patient over a duration of time due to consumption of the meal based on the contextual information for the meal, determining one or more amounts of insulin to counteract effects of the predicted amounts of glucose, and affecting insulin therapy based on outputting information indicative of the determined one or more amounts of insulin.

Claims (34)

1 . A system for dosage recommendation, the system comprising:

one or more processors; and

one or more processor-readable storage media storing instructions which, when executed by the one or more processors, cause performance of:

obtaining contextual information for a meal;

utilizing an artificial intelligence technique to determine, based on the contextual information for the meal, a dosage of insulin that corresponds to a maximum amount of time within a target range for a patient's glucose levels; and

affecting insulin therapy of the patient based on outputting information indicative of the determined dosage.

2 . The system of claim 1 , wherein utilizing the artificial intelligence technique comprises using genetic programming to determine the dosage of insulin that corresponds to a maximum amount of time within a target range for the patient's glucose levels.

3 . The system of claim 1 , wherein utilizing the artificial intelligence technique comprises predicting amounts of glucose to be absorbed into a bloodstream of the patient over a duration of time.

4 . The system of claim 3 , wherein the amounts of glucose comprises a first amount of glucose to be absorbed into the bloodstream at a first time instance within the duration of time, and a second amount of glucose to be absorbed into the bloodstream at a second time instance within the duration of time.

5 . The system of claim 1 , wherein affecting the insulin therapy comprises:

communicating towards an insulin delivery device the information indicative of the determined dosage.

6 . The system of claim 5 , wherein the insulin delivery device is an injection device configured to automatically set an insulin level based on the information indicative of the determined dosage.

7 . The system of claim 5 , wherein the insulin delivery device is an insulin pump configured to automatically deliver the determined dosage to the patient.

8 . A processor-implemented method for dosage recommendation, the method comprising:

obtaining contextual information for a meal;

utilizing an artificial intelligence technique to determine, based on the contextual information for the meal, a dosage of insulin that corresponds to a maximum amount of time within a target range for a patient's glucose levels; and

affecting insulin therapy of the patient based on outputting information indicative of the determined dosage.

9 . The method of claim 8 , wherein utilizing the artificial intelligence technique comprises using genetic programming to determine the dosage of insulin that corresponds to a maximum amount of time within a target range for the patient's glucose levels.

10 . The method of claim 8 , wherein utilizing the artificial intelligence technique comprises predicting amounts of glucose to be absorbed into a bloodstream of the patient over a duration of time.

11 . The method of claim 10 , wherein the amounts of glucose comprises a first amount of glucose to be absorbed into the bloodstream at a first time instance within the duration of time, and a second amount of glucose to be absorbed into the bloodstream at a second time instance within the duration of time.

12 . The method of claim 8 , wherein affecting the insulin therapy comprises:

communicating towards an insulin delivery device the information indicative of the determined dosage.

13 . The method of claim 12 , wherein the insulin delivery device is an injection device configured to automatically set an insulin level based on the information indicative of the determined dosage.

14 . The method of claim 12 , wherein the insulin delivery device is an insulin pump configured to automatically deliver the determined dosage to the patient.

15 . One or more non-transitory processor-readable storage media storing instructions which, when executed by one or more processors, cause performance of:

obtaining contextual information for a meal;

utilizing an artificial intelligence technique to determine, based on the contextual information for the meal, a dosage of insulin that corresponds to a maximum amount of time within a target range for a patient's glucose levels; and

affecting insulin therapy of the patient based on outputting information indicative of the determined dosage.

16 . The one or more non-transitory processor-readable storage media of claim 15 , wherein utilizing the artificial intelligence technique comprises using genetic programming to determine the dosage of insulin that corresponds to a maximum amount of time within a target range for the patient's glucose levels.

17 . The one or more non-transitory processor-readable storage media of claim 15 , wherein utilizing the artificial intelligence technique comprises predicting amounts of glucose to be absorbed into a bloodstream of the patient over a duration of time.

18 . The one or more non-transitory processor-readable storage media of claim 17 , wherein the amounts of glucose comprises a first amount of glucose to be absorbed into the bloodstream at a first time instance within the duration of time, and a second amount of glucose to be absorbed into the bloodstream at a second time instance within the duration of time.

19 . The one or more non-transitory processor-readable storage media of claim 15 , wherein affecting the insulin therapy comprises:

communicating towards an injection device the information indicative of the determined dosage.

20 . The one or more non-transitory processor-readable storage media of claim 19 , wherein affecting the insulin therapy comprises communicating towards an insulin pump the information indicative of the determined dosage.

Assignments (2)
SECURITY INTEREST Recorded Jan 16, 2026
From: MEDTRONIC MINIMED, INC.; COMPANION MEDICAL, INC.
To: CITIBANK, N.A.
Reel/Frame 074394/0237 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 29, 2021
From: JIANG, BOYI; ZHONG, YUXIANG; AGRAWAL, PRATIK J.; DIANATY, ALI
To: MEDTRONIC MINIMED, INC.
Reel/Frame 055077/0272 →